Drug Guideline – Use of molnupiravir capsules for COVID-19

molnupiravir dose  The approved human molnupiravir formulation is 200 mg in capsule form, but must be divided into smaller dosage components for animals to No dose adjustment of LAGEVRIO is required in patients with renal impairment

The infected hamsters were treated twice daily with the vehicle or a suboptimal dose of each compound or a combination of both compounds  The selection of the suboptimal Molnupiravir dose was based on a dose-response study against the WT strain that we have previously published in

They received molnupiravir at a dosage of 800 mg twice daily for 5 days for mild-to-moderate COVID-19 Molnupiravir was safe and well tolerated; a dose of 800mg twice-daily for 5 days was recommended for Phase II evaluation Background AGILE is a phase IbIIa